In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma

By Baratti D.  

Annals of Surgical Oncology, Vol. 17, Iss. 6, 2010-06 ,pp. : 1713-1714

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

By McQuellon Richard   Danhauer Suzanne   Russell Gregory   Shen Perry   Fenstermaker Joyce   Stewart John   Levine Edward  

Annals of Surgical Oncology, Vol. 14, Iss. 3, 2007-03 ,pp. : 1105-1113

Springer Publishing Company

Access to resources Recommend Favorite

Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin

By Blackham Aaron  

Annals of Surgical Oncology, Vol. 17, Iss. 10, 2010-10 ,pp. : 2720-2727

Springer Publishing Company

Access to resources Recommend Favorite

Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy

By Tuttle Todd   Zhang Yan   Greeno Edward   Knutsen Amy  

Annals of Surgical Oncology, Vol. 13, Iss. 12, 2006-12 ,pp. : 1627-1632

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma †

By Yan Tristan   Brun Erwin   Cerruto Carlos   Haveric Namik   Chang David   Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 14, Iss. 1, 2007-01 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite